Glycotransferase Inhibitor in Covid Patients | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals

+44 7389645282

Archives of Applied Science Research


Glycotransferase Inhibitor in Covid Patients

Author(s): Eliza Hessy

Extreme intense respiratory condition Covid 2 (SARS-CoV-2) goes through blood classification explicit
glycosylation which has suggestions for contamination weakness and replication without identification from the safe
framework. SARS-CoV-2 commandeers the host cell glycotransferase bringing about spike protein glycosylation
looking like blood classification antigens. Disease hazard associates to blood classifications that don’t have against An
or potentially hostile to B antibodies like that seen for ABO blood classification beneficiaries. The general beneficiary
AB is profoundly vulnerable to disease lacking both enemy of An and B antibodies, though blood classification O
has the two antibodies bringing about less danger of contamination.